Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

BACKGROUND: Therapeutic options for inflammatory bowel disease (IBD) have increased since the introduction of tumour necrosis factor (TNF) inhibitors a few decades ago. However, direct comparisons of the effectiveness of second-line biological agents in patients with ulcerative colitis (UC) and Croh...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyun, Hye Kyung, Zhang, Hyun-Soo, Yu, Jongwook, Kang, Eun Ae, Park, Jihye, Park, Soo Jung, Park, Jae Jun, Kim, Tae Il, Kim, Won Ho, Cheon, Jae Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958783/
https://www.ncbi.nlm.nih.gov/pubmed/35346063
http://dx.doi.org/10.1186/s12876-022-02225-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958783/
https://www.ncbi.nlm.nih.gov/pubmed/35346063
http://dx.doi.org/10.1186/s12876-022-02225-w

Ejemplares similares